A population‐based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination

摘要: Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these in real-world clinical settings must still determined. Toward this end, an ongoing statewide surveillance program was established New Mexico assess all aspects cervical cancer preventive care. Given that reduction incidence is expected take several decades manifest, a systematic population-based measurement type-specific prevalence employing age- cytology-stratified sample 47,617 women attending screening conducted prior widespread vaccination. A well-validated polymerase chain reaction (PCR) method 37 genotypes used test liquid-based cytology specimens. The any types 27.3% overall with maximum 52% at age 20 years followed by rapid decline older ages. prevalences aged ≤ years, 21-29 or ≥ 30 were 9.6, 6.5 1.8%, respectively. combined groups 12.0, 8.3 2.4%, and/or detected 54.5% high-grade squamous intraepithelial (cytologic) (HSIL) 25.0% those low-grade SIL (LSIL). These baseline data enable estimates vaccine impact across time provide critical reference measurements important assessing benefits potential harms vaccination including increases nonvaccine (i.e., type replacement).